InfuSystem (INFU) 10-Q 10 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	May. 03, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	INFU
Entity Registrant Name	InfuSystem Holdings, Inc
Entity Central Index Key	1,337,013
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		22,623,987

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 569	$ 818
Accounts receivable, less allowance for doubtful accounts of $5,058 and $4,737 at March 31, 2016 and December 31, 2015, respectively	15,359	14,206
Inventory	2,622	1,916
Other current assets	1,087	861
Deferred income taxes	2,743	2,743
Total Current Assets	22,380	20,544
Medical equipment held for sale or rental	2,426	2,277
Medical equipment in rental service, net of accumulated depreciation	29,799	27,837
Property & equipment, net of accumulated depreciation	2,308	2,370
Intangible assets, net	31,833	31,534
Deferred income taxes	11,158	11,502
Other assets	260	251
Total Assets	100,164	96,315
Current Liabilities:
Accounts payable	8,014	6,586
Current portion of long-term debt	5,177	5,060
Other current liabilities	2,462	3,641
Total Current Liabilities	15,653	15,287
Long-term debt, net of current portion	32,433	29,750
Total Liabilities	$ 48,086	$ 45,037
Stockholders' Equity:
Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued
Common stock, $.0001 par value: authorized 200,000,000 shares; issued and outstanding 22,767,052 and 22,569,392, respectively, as of March 31, 2016 and 22,739,550 and 22,541,890, respectively, as of December 31, 2015	$ 2	$ 2
Additional paid-in capital	91,543	91,238
Retained deficit	(39,467)	(39,962)
Total Stockholders' Equity	52,078	51,278
Total Liabilities and Stockholders' Equity	$ 100,164	$ 96,315

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 5,058	$ 4,737
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	22,767,052	22,739,550
Common stock, shares outstanding	22,569,392	22,541,890

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net revenues:
Rentals	$ 17,238	$ 15,139
Product Sales	1,806	1,586
Net revenues	19,044	16,725
Cost of revenues:
Cost of revenues - Product, service and supply costs	3,506	3,015
Cost of revenues - Pump depreciation and disposals	2,231	1,621
Gross profit	13,307	12,089
Selling, general and administrative expenses:
Provision for doubtful accounts	1,747	1,194
Amortization of intangibles	912	631
Selling and marketing	2,815	2,737
General and administrative	6,669	5,975
Total selling, general and administrative	12,143	10,537
Operating income	1,164	1,552
Other income (expense):
Interest expense	(305)	(672)
Loss on extinguishment of long term debt		(1,599)
Other income	20	19
Total other expense	(285)	(2,252)
Income (loss) before income taxes	879	(700)
Income tax (expense) benefit	(384)	285
Net income (loss)	$ 495	$ (415)
Net income (loss) per share:
Basic	$ 0.02	$ (0.02)
Diluted	$ 0.02	$ (0.02)
Weighted average shares outstanding:
Basic	22,548,538	22,308,730
Diluted	23,039,256	22,308,730

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement of Cash Flows [Abstract]
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	$ 337	$ (1,392)
INVESTING ACTIVITIES
Purchase of medical equipment and property	(3,274)	(3,670)
Proceeds from sale of medical equipment and property	884	1,118
NET CASH USED IN INVESTING ACTIVITIES	(2,390)	(2,552)
FINANCING ACTIVITIES
Principal payments on revolving credit facility, term loans and capital lease obligations	(15,369)	(39,180)
Cash proceeds from revolving credit facility	17,081	45,980
Debt issuance costs		(147)
Common stock repurchased to satisfy statutory withholding on employee stock based compensation plans	(33)
Cash proceeds from stock plans	125
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,804	6,653
Net change in cash and cash equivalents	(249)	2,709
Cash and cash equivalents, beginning of period	818	515
Cash and cash equivalents, end of period	$ 569	$ 3,224

Basis of Presentation, Nature o

Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies	1. Basis of Presentation, Nature of Operations and Summary of Significant Accounting Policies The terms “InfuSystem”, “the Company”, “we”, “our” and “us” are used herein to refer to InfuSystem Holdings, Inc. and its subsidiaries. InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services. The Company services hospitals, oncology practices and other alternative site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support, and also operates pump repair Centers of Excellence in Michigan, Kansas, California, Texas, Georgia and Ontario, Canada. The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. Generally Accepted Accounting Principles (“GAAP”) for complete financial statements. The accompanying unaudited condensed consolidated financial statements include all adjustments, composed of normal recurring adjustments, considered necessary by management to fairly state the Company’s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 as filed with the SEC. The unaudited condensed consolidated financial statements are prepared in conformity with GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods.

Business Combination

Business Combination	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Business Combination	2. Business Combination On April 20, 2015 (the “Closing Date”), the Company acquired substantially all of the assets of Ciscura Holding Company, Inc. and its subsidiaries (“Ciscura”) for $6.2 million in cash, based on the final number of pumps acquired and the associated treatments, which were generated during the 90-day period post-closing from the approximately 100 medical facility relationships Ciscura had prior to the acquisition. The Company acquired approximately 1,800 infusion pumps, its four-person field sales team, as well as its facilities management personnel, which have become the foundation of the Company’s new Southeast facility. Ciscura, based in Alpharetta, GA, was a privately-held Southeastern regional provider of ambulatory infusion pumps and services to medical facilities and provides the Company with a new regional warehouse and service facility that are in close proximity to a number of our largest existing customers, in addition to new customers previously serviced by Ciscura, enabling same day service for equipment and supplies to much of the Southeast region. The Company used available borrowings under its Credit Facility to finance the acquisition and associated expenses. Final Purchase Price Allocation Pursuant to Accounting Standards Codification (“ASC”) 805, Business Combinations, the final purchase price was allocated to the assets acquired and liabilities assumed based upon their fair values as of the Closing Date. The final purchase price allocation was primarily based upon a valuation using income and cost approaches and management’s estimates and assumptions. The allocation of the final purchase price to the fair values of the assets acquired and liabilities assumed as of the Closing Date is presented below (in thousands): Amount Medical equipment in rental service $ 2,289 Trade names and Trademarks 23 Customer relationships 3,393 Furniture and fixtures 20 Leasehold improvements 185 Non-competition agreements 246 Total - final purchase price $ 6,156 Acquired property and equipment are being depreciated on a straight-line basis with estimated remaining lives ranging from 1 year to 7 years. Unaudited Pro Forma Financial Information The unaudited pro forma financial information in the table below summarizes the combined results of operations of the Company and Ciscura as though the companies had been combined as of the beginning of the three month period ended March 31, 2015. The pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of the period presented nor is it indicative of future results. The Company did not disclose the revenue and income of Ciscura separately as it is not practical due to the fact that the operations are substantially integrated. The following pro forma financial information presented also includes the pro forma depreciation and amortization charges from acquired tangible and intangible assets, and related tax effects for the three months ended March 31, 2015 (in thousands): Three months ended March 31, 2015 Revenue $ 17,591 Net income $ (326 )

Medical Equipment and Property

Medical Equipment and Property	3 Months Ended
	Mar. 31, 2016
Text Block [Abstract]
Medical Equipment and Property	3. Medical Equipment and Property Medical equipment consisted of the following as of March 31, 2016 and December 31, 2015 (in thousands): March 31, December 31, Medical Equipment held for sale or rental $ 2,426 $ 2,277 Medical Equipment in rental service 56,785 53,681 Medical Equipment in rental service - pump reserve (291 ) (232 ) Accumulated depreciation (26,695 ) (25,612 ) Medical Equipment in rental service - net 29,799 27,837 Total $ 32,225 $ 30,114 Depreciation expense for medical equipment for the three months ended March 31, 2016 was $1.5 million, compared to $1.0 million for the same prior year period, which was recorded in cost of revenues – pump depreciation and disposals, for each period. Depreciation expense for property and equipment for the three months ended March 31, 2016 and 2015 was $0.1 million. This expense was recorded in general and administrative expenses.

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	4. Intangible Assets The carrying amount and accumulated amortization of intangible assets as of March 31, 2016 and December 31, 2015, are as follows (in thousands): March 31, 2016 Gross Assets Accumulated Net Nonamortizable intangible assets Trade names $ 2,000 $ — $ 2,000 Amortizable intangible assets Trade names 23 21 2 Physician and customer relationships 32,865 17,493 15,372 Physician and customer relationships - Ciscura 3,394 156 3,238 Non-competition agreements 1,094 961 133 Software 11,717 629 11,088 Total nonamortizable and amortizable intangible assets $ 51,093 $ 19,260 $ 31,833 December 31, 2015 Gross Assets Accumulated Net Nonamortizable intangible assets Trade names $ 2,000 $ — $ 2,000 Amortizable intangible assets Trade names 23 15 8 Physician and customer relationships 32,865 16,946 15,919 Physician and customer relationships - Ciscura 3,393 103 3,290 Non-competition agreements 1,094 930 164 Software 11,942 1,789 10,153 Total nonamortizable and amortizable intangible assets $ 51,317 $ 19,783 $ 31,534 Amortization expense for the three months ended March 31, 2016 was $0.9 million compared to $0.6 million for the three months ended March 31, 2015. Expected annual amortization expense for intangible assets recorded as of March 31, 2016, is as follows (in thousands): 4/1- 12/31/2016 2017 2018 2019 2020 2021 and Amortization expense $ 4,158 $ 5,301 $ 4,936 $ 5,451 $ 2,590 $ 7,397

Debt

Debt	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Debt	5. Debt On March 23, 2015, the Company and its direct and indirect subsidiaries (the “Borrowers”) entered into a credit agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as lender (the “Lender”). The Credit Agreement consists of a $27.0 million Term Loan A, up to an $8.0 million Term Loan B and a $10.0 million revolving credit facility (the “Revolver”), all of which mature on March 23, 2020, collectively (the “Credit Facility”). On March 23, 2015, the Borrowers drew $27.0 million under the Term A Loan to repay and terminate the previously existing credit facility under the credit agreement dated November 30, 2012, as amended, by and among the Company, its direct and indirect subsidiaries, Wells Fargo Bank, National Association, as administrative agent, and certain lenders party thereto (the “WF Facility”). As of March 31, 2016, Term Loan B had a balance of $6.1 million. As of March 31, 2016, interest on the Credit Facility is payable at the Borrowers’ choice as a (i) Eurodollar Loan, which bears interest at a per annum rate equal to LIBOR, plus a margin ranging from 2.00% to 2.50% or (ii) CBFR Loan, which bears interest at a per annum rate equal to (a) the Lender’s prime rate or (b) LIBOR for a 30-day interest period, plus 2.50%, in each case, plus a margin ranging from -0.75% to -0.25%. The actual rate at March 31, 2016 was 2.93% (LIBOR of 0.43% plus 2.50%). The availability under the Revolver is based upon the Borrowers’ eligible accounts receivable and eligible inventory and is comprised as follows (in thousands): March 31, December 31, Revolver: Gross Availability $ 10,000 $ 10,000 Outstanding Draws (3,780 ) — Letter of Credit — (81 ) Landlord Reserves (45 ) (37 ) Availability on Revolver $ 6,175 $ 9,882 To secure repayment of the obligations of the Borrowers, each Borrower has granted to the Lender, for the benefit of various secured parties, a first priority security interest in substantially all of the personal property assets of each of the Borrowers. In addition, the Company has pledged the shares of InfuSystem Holdings USA, Inc. (“Holdings USA”) and Holdings USA has pledged the shares of each of InfuSystem, Inc. and First Biomedical, Inc. and the equity interests of IFC, LLC to the Lender, for the benefit of the secured parties, to further secure the obligations under the Credit Agreement. In addition, the Credit Agreement requires the Borrowers to maintain the following financial covenant obligations: (i) a minimum fixed charge coverage ratio of 1.25:1.00; (ii) a maximum total leverage ratio ranging from 3.00:1.00 to 2.25:1.00 during specified periods; and (iii) a minimum net worth of $37.5 million As of March 31, 2016, the Borrowers were in compliance with all such covenants. The Company occasionally enters into capital leases to finance the purchase of ambulatory infusion pumps. The pumps are capitalized into medical equipment in rental service at their fair market value, which equals the value of the future minimum lease payments and are depreciated over the useful life of the pumps. The Company had approximate future maturities of loans and capital leases as of March 31, 2016 as follows (in thousands): 2016 2017 2018 2019 2020 Total Term Loan A (a) $ — $ 3,860 $ 3,860 $ 3,860 $ 9,630 $ 21,210 Term Loan B 681 908 1,136 1,136 2,261 6,122 Unamortized value of the debt issuance costs (b) (25 ) (31 ) (31 ) (31 ) (8 ) (126 ) Revolver — — — — 3,780 3,780 Capital Leases 2,585 2,561 1,361 117 — 6,624 Total $ 3,241 $ 7,298 $ 6,326 $ 5,082 $ 15,663 $ 37,610 (a) The Company has prepaid its Term Loan A principal payments due on June 30, 2016, September 30, 2016 and December 31, 2016. Each of these payments is $965, representing a total prepayment of $2,895 (b) Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03 The following is a breakdown of the Company’s current and long-term debt (including capital leases) as of March 31, 2016 and December 31, 2015 (in thousands): March 31, 2016 December 31, 2015 Current Long-Term Long-Term Total Current Long-Term Long-Term Total Term Loans $ 1,873 $ 25,459 $ 27,332 Term Loans $ 1,873 $ 26,651 $ 28,524 Unamortized value of the debt issuance costs (a) $ — $ (126 ) (126 ) Unamortized value of the debt issuance costs (a) $ — $ (134 ) (134 ) Revolver — 3,780 3,780 Revolver — — — Capital Leases 3,304 3,320 6,624 Capital Leases 3,187 3,233 6,420 Total $ 5,177 $ 32,433 $ 37,610 Total $ 5,060 $ 29,750 $ 34,810 (a) Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes During the three months ended March 31, 2016, the Company recorded income tax expense of $0.4 million. The Company recorded an income tax benefit of $0.3 million for the same prior year period. In computing its income tax provision, the Company estimates its effective tax rate for the full year and applies that rate to income earned through the reporting period. The Company’s effective income tax rate for the three months ended March 31, 2016 was 40.9% compared to 40.8% for the same prior year period.

Commitments, Contingencies and

Commitments, Contingencies and Litigation	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Litigation	7. Commitments, Contingencies and Litigation From time to time in the ordinary course of its business, the Company may be involved in legal proceedings, the outcomes of which may not be determinable. The Company has insurance policies covering potential losses where such coverage is cost effective. The Company is not, at this time, involved in any legal proceedings that the Company believes could have a material effect on the Company’s financial condition, results of operations or cash flows.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	8. Earnings (Loss) Per Share Basic income (loss) per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share assumes the issuance of potentially dilutive shares of common stock during the period. The following table reconciles the numerators and denominators of the basic and diluted income (loss) per share computations: Three Months Ended March 31 2016 2015 Numerator: Net income (loss) (in thousands) $ 495 $ (415 ) Denominator: Weighted average common shares outstanding: Basic 22,548,538 22,308,730 Dilutive effect of non-vested awards 490,718 — Diluted 23,039,256 22,308,730 Net income (loss) per share: Basic $ 0.02 $ (0.02 ) Diluted $ 0.02 $ (0.02 ) For the three months ended March 31, 2016, 0.1 million of stock options were not included in the calculation because they would have an anti-dilutive effect. For the three months ended March 31, 2015, 0.3 million of stock options were not included in the calculation because they would have an anti-dilutive effect.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	9. Subsequent Events The Company has evaluated subsequent events through the date of issuance for the unaudited condensed consolidated financial statements.

Recent Accounting Pronouncement

Recent Accounting Pronouncements and Developments	3 Months Ended
	Mar. 31, 2016
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements and Developments	10. Recent Accounting Pronouncements and Developments In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”), and, in August 2015, the FASB issued ASU No. 2015-15, Interest – Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements – Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (“ASU 2015-15”). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-15 then clarified that debt issuance costs related to a line-of-credit arrangement can be presented as an asset on the balance sheet, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. These ASUs are effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. The Company adopted this guidance as of January 1, 2016, and as a result, have recast the December 31, 2015 consolidated balance sheet to conform to the current period presentation. The adoption of this standard reduced previously presented other assets and long-term debt by $0.1 million, based upon the balance of unamortized debt issuance costs relating to its Credit Facility as of December 31, 2015. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory (“ASU 2015-11”), requiring that inventory be measured at the lower of cost and net realizable value. Net realizable value is defined as estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. ASU 2015-11 is effective within annual periods beginning on or after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures. On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will supersede the existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either a retrospective or cumulative effect transition method. In August 2015, the FASB issued ASU No. 2015-14, deferring the effective date of ASU 2014-09 by one year, from January 1, 2017 to January 1, 2018. The Company plans to adopt ASU 2014-09 on January 1, 2018. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures and has not yet selected a transition method nor has the Company determined the effect of the standard on its ongoing financial reporting. In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments (“ASU 2015-16”), requiring that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. ASU 2015-16 also requires an entity to present separately on the face of the income statement, or disclose in the notes to the financial statements, the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. ASU 2015-16 is effective within annual periods beginning on or after December 15, 2015, including interim periods within that reporting period, and will be applied prospectively to measurement-period adjustments that occur after the effective date of this ASU. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures. In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes (“ASU 2015-17”), simplifying the balance sheet classification of deferred taxes by requiring all deferred taxes, along with any related valuation allowance, to be presented as noncurrent. ASU 2015-17 is effective for the Company beginning in the first quarter of 2017 and allows for early adoption and may be applied either prospectively or retrospectively. ASU 2015-17 is not expected to have a material impact on the Company’s financial position, results of operations, cash flows and/or disclosures. In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 2016-01”). The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures.

Business Combination (Policies)

Business Combination (Policies)	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Business Combinations	Final Purchase Price Allocation Pursuant to Accounting Standards Codification (“ASC”) 805, Business Combinations, the final purchase price was allocated to the assets acquired and liabilities assumed based upon their fair values as of the Closing Date. The final purchase price allocation was primarily based upon a valuation using income and cost approaches and management’s estimates and assumptions. The allocation of the final purchase price to the fair values of the assets acquired and liabilities assumed as of the Closing Date is presented below (in thousands): Amount Medical equipment in rental service $ 2,289 Trade names and Trademarks 23 Customer relationships 3,393 Furniture and fixtures 20 Leasehold improvements 185 Non-competition agreements 246 Total - final purchase price $ 6,156 Acquired property and equipment are being depreciated on a straight-line basis with estimated remaining lives ranging from 1 year to 7 years.
Recent Accounting Pronouncements and Developments	In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”), and, in August 2015, the FASB issued ASU No. 2015-15, Interest – Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements – Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (“ASU 2015-15”). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-15 then clarified that debt issuance costs related to a line-of-credit arrangement can be presented as an asset on the balance sheet, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. These ASUs are effective for fiscal years beginning after December 15, 2015, and for interim periods within those fiscal years. The Company adopted this guidance as of January 1, 2016, and as a result, have recast the December 31, 2015 consolidated balance sheet to conform to the current period presentation. The adoption of this standard reduced previously presented other assets and long-term debt by $0.1 million, based upon the balance of unamortized debt issuance costs relating to its Credit Facility as of December 31, 2015. In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory (“ASU 2015-11”), requiring that inventory be measured at the lower of cost and net realizable value. Net realizable value is defined as estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. ASU 2015-11 is effective within annual periods beginning on or after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures. On May 28, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will supersede the existing revenue recognition guidance in U.S. GAAP when it becomes effective and permits the use of either a retrospective or cumulative effect transition method. In August 2015, the FASB issued ASU No. 2015-14, deferring the effective date of ASU 2014-09 by one year, from January 1, 2017 to January 1, 2018. The Company plans to adopt ASU 2014-09 on January 1, 2018. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures and has not yet selected a transition method nor has the Company determined the effect of the standard on its ongoing financial reporting. In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments (“ASU 2015-16”), requiring that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. ASU 2015-16 also requires an entity to present separately on the face of the income statement, or disclose in the notes to the financial statements, the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. ASU 2015-16 is effective within annual periods beginning on or after December 15, 2015, including interim periods within that reporting period, and will be applied prospectively to measurement-period adjustments that occur after the effective date of this ASU. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures. In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes (“ASU 2015-17”), simplifying the balance sheet classification of deferred taxes by requiring all deferred taxes, along with any related valuation allowance, to be presented as noncurrent. ASU 2015-17 is effective for the Company beginning in the first quarter of 2017 and allows for early adoption and may be applied either prospectively or retrospectively. ASU 2015-17 is not expected to have a material impact on the Company’s financial position, results of operations, cash flows and/or disclosures. In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments – Overall: Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 2016-01”). The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). Under ASU 2016-02, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its financial position, results of operations, cash flows and/or disclosures.

Business Combination (Tables)

Business Combination (Tables)	3 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Summary of Final Purchase Price Allocation	The allocation of the final purchase price to the fair values of the assets acquired and liabilities assumed as of the Closing Date is presented below (in thousands): Amount Medical equipment in rental service $ 2,289 Trade names and Trademarks 23 Customer relationships 3,393 Furniture and fixtures 20 Leasehold improvements 185 Non-competition agreements 246 Total - final purchase price $ 6,156
Summary of Pro Forma Financial Information Includes Depreciation and Amortization Charges	The following pro forma financial information presented also includes the pro forma depreciation and amortization charges from acquired tangible and intangible assets, and related tax effects for the three months ended March 31, 2015 (in thousands): Three months ended March 31, 2015 Revenue $ 17,591 Net income $ (326 )

Medical Equipment and Property

Medical Equipment and Property (Tables)	3 Months Ended
	Mar. 31, 2016
Text Block [Abstract]
Summary of Medical Equipment	Medical equipment consisted of the following as of March 31, 2016 and December 31, 2015 (in thousands): March 31, December 31, Medical Equipment held for sale or rental $ 2,426 $ 2,277 Medical Equipment in rental service 56,785 53,681 Medical Equipment in rental service - pump reserve (291 ) (232 ) Accumulated depreciation (26,695 ) (25,612 ) Medical Equipment in rental service - net 29,799 27,837 Total $ 32,225 $ 30,114

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets	The carrying amount and accumulated amortization of intangible assets as of March 31, 2016 and December 31, 2015, are as follows (in thousands): March 31, 2016 Gross Assets Accumulated Net Nonamortizable intangible assets Trade names $ 2,000 $ — $ 2,000 Amortizable intangible assets Trade names 23 21 2 Physician and customer relationships 32,865 17,493 15,372 Physician and customer relationships - Ciscura 3,394 156 3,238 Non-competition agreements 1,094 961 133 Software 11,717 629 11,088 Total nonamortizable and amortizable intangible assets $ 51,093 $ 19,260 $ 31,833 December 31, 2015 Gross Assets Accumulated Net Nonamortizable intangible assets Trade names $ 2,000 $ — $ 2,000 Amortizable intangible assets Trade names 23 15 8 Physician and customer relationships 32,865 16,946 15,919 Physician and customer relationships - Ciscura 3,393 103 3,290 Non-competition agreements 1,094 930 164 Software 11,942 1,789 10,153 Total nonamortizable and amortizable intangible assets $ 51,317 $ 19,783 $ 31,534
Schedule of Expected Annual Amortization Expense for Intangible Assets	Expected annual amortization expense for intangible assets recorded as of March 31, 2016, is as follows (in thousands): 4/1- 12/31/2016 2017 2018 2019 2020 2021 and Amortization expense $ 4,158 $ 5,301 $ 4,936 $ 5,451 $ 2,590 $ 7,397

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Summary of Revolver Based upon Borrowers' Eligible Accounts Receivable and Inventory	The availability under the Revolver is based upon the Borrowers’ eligible accounts receivable and eligible inventory and is comprised as follows (in thousands): March 31, December 31, Revolver: Gross Availability $ 10,000 $ 10,000 Outstanding Draws (3,780 ) — Letter of Credit — (81 ) Landlord Reserves (45 ) (37 ) Availability on Revolver $ 6,175 $ 9,882
Summary of Future Maturities of Loans and Capital Leases	The Company had approximate future maturities of loans and capital leases as of March 31, 2016 as follows (in thousands): 2016 2017 2018 2019 2020 Total Term Loan A (a) $ — $ 3,860 $ 3,860 $ 3,860 $ 9,630 $ 21,210 Term Loan B 681 908 1,136 1,136 2,261 6,122 Unamortized value of the debt issuance costs (b) (25 ) (31 ) (31 ) (31 ) (8 ) (126 ) Revolver — — — — 3,780 3,780 Capital Leases 2,585 2,561 1,361 117 — 6,624 Total $ 3,241 $ 7,298 $ 6,326 $ 5,082 $ 15,663 $ 37,610 (a) The Company has prepaid its Term Loan A principal payments due on June 30, 2016, September 30, 2016 and December 31, 2016. Each of these payments is $965, representing a total prepayment of $2,895 (b) Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03
Summary of Company's Current and Long-Term Debt (Including Capital Leases)	The following is a breakdown of the Company’s current and long-term debt (including capital leases) as of March 31, 2016 and December 31, 2015 (in thousands): March 31, 2016 December 31, 2015 Current Long-Term Long-Term Total Current Long-Term Long-Term Total Term Loans $ 1,873 $ 25,459 $ 27,332 Term Loans $ 1,873 $ 26,651 $ 28,524 Unamortized value of the debt issuance costs (a) $ — $ (126 ) (126 ) Unamortized value of the debt issuance costs (a) $ — $ (134 ) (134 ) Revolver — 3,780 3,780 Revolver — — — Capital Leases 3,304 3,320 6,624 Capital Leases 3,187 3,233 6,420 Total $ 5,177 $ 32,433 $ 37,610 Total $ 5,060 $ 29,750 $ 34,810 (a) Includes the reclassification of the debt issuance costs as a result of the Company adopting ASU 2015-03

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Numerators and Denominators of Basic and Diluted Income (Loss) per Share	The following table reconciles the numerators and denominators of the basic and diluted income (loss) per share computations: Three Months Ended March 31 2016 2015 Numerator: Net income (loss) (in thousands) $ 495 $ (415 ) Denominator: Weighted average common shares outstanding: Basic 22,548,538 22,308,730 Dilutive effect of non-vested awards 490,718 — Diluted 23,039,256 22,308,730 Net income (loss) per share: Basic $ 0.02 $ (0.02 ) Diluted $ 0.02 $ (0.02 )

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - Ciscura [Member] $ in Millions	Apr. 20, 2015USD ($)Medical_FacilityInfusionPump	Mar. 31, 2016
Business Acquisition [Line Items]
Purchase price | $	$ 6.2
Number of medical facility relationships prior to acquisition | Medical_Facility	100
Number of infusion pumps acquired | InfusionPump	1,800
Minimum [Member]
Business Acquisition [Line Items]
Property and equipment, estimated remaining lives		1 year
Maximum [Member]
Business Acquisition [Line Items]
Property and equipment, estimated remaining lives		7 years

Business Combinations - Summary

Business Combinations - Summary of Final Purchase Price Allocation (Detail) - Ciscura [Member] $ in Thousands	Apr. 20, 2015USD ($)
Business Acquisition [Line Items]
Medical equipment in rental service	$ 2,289
Total - final purchase price	6,156
Furniture, Fixtures, and Equipment [Member]
Business Acquisition [Line Items]
Property, plant, and equipment	20
Leasehold Improvements [Member]
Business Acquisition [Line Items]
Property, plant, and equipment	185
Trademarks and Trade Names [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets	23
Customer Relationships [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets	3,393
Non-Compete Agreements [Member]
Business Acquisition [Line Items]
Finite-lived intangible assets	$ 246

Business Combinations - Summa24

Business Combinations - Summary of Pro Forma Financial Information Includes Depreciation and Amortization Charges (Detail) - Ciscura [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2015USD ($)
Business Acquisition [Line Items]
Revenue	$ 17,591
Net income	$ (326)

Medical Equipment and Propert25

Medical Equipment and Property - Summary of Medical Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Medical Equipment And Property [Abstract]
Medical equipment held for sale or rental	$ 2,426	$ 2,277
Medical Equipment in rental service	56,785	53,681
Medical Equipment in rental service - pump reserve	(291)	(232)
Accumulated depreciation	(26,695)	(25,612)
Medical Equipment in rental service - net	29,799	27,837
Total	$ 32,225	$ 30,114

Medical Equipment and Propert26

Medical Equipment and Property - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense for medical equipment	$ 1.5	$ 1
Total depreciation expense recorded	$ 0.1	$ 0.1

Intangible Assets - Summary of

Intangible Assets - Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Total nonamortizable and amortizable intangible assets, Gross Assets	$ 51,093	$ 51,317
Total nonamortizable and amortizable intangible assets, Accumulated Amortization	19,260	19,783
Total nonamortizable and amortizable intangible assets, Net	31,833	31,534
Trade Names [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	23	23
Amortizable intangible assets, Accumulated Amortization	21	15
Amortizable intangible assets, Net	2	8
Physician and Customer Relationships [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	32,865	32,865
Amortizable intangible assets, Accumulated Amortization	17,493	16,946
Amortizable intangible assets, Net	15,372	15,919
Non-Compete Agreements [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	1,094	1,094
Amortizable intangible assets, Accumulated Amortization	961	930
Amortizable intangible assets, Net	133	164
Software [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	11,717	11,942
Amortizable intangible assets, Accumulated Amortization	629	1,789
Amortizable intangible assets, Net	11,088	10,153
Ciscura [Member] | Physician and Customer Relationships [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Amortizable intangible assets, Gross Assets	3,394	3,393
Amortizable intangible assets, Accumulated Amortization	156	103
Amortizable intangible assets, Net	3,238	3,290
Trade Names [Member]
Indefinite Lived And Finite Lived Intangible Assets [Line Items]
Nonamortizable intangible assets	$ 2,000	$ 2,000

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 912	$ 631

Intangible Assets - Schedule of

Intangible Assets - Schedule of Expected Annual Amortization Expense for Intangible Assets (Detail) $ in Thousands	Mar. 31, 2016USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense, 2016	$ 4,158
Amortization expense, 2017	5,301
Amortization expense, 2018	4,936
Amortization expense, 2019	5,451
Amortization expense, 2020	2,590
Amortization expense, 2021 and thereafter	$ 7,397

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Mar. 31, 2016	Mar. 31, 2016	Dec. 31, 2015	Mar. 23, 2015
JP Morgan Chase Bank [Member]
Line of Credit Facility [Line Items]
Credit facility, maturity date		Mar. 23, 2020
Term Loan A [Member]
Line of Credit Facility [Line Items]
Current borrowings under credit facility				$ 27,000,000
Term Loan A [Member] | JP Morgan Chase Bank [Member]
Line of Credit Facility [Line Items]
Line of credit facility				27,000,000
Term Loan B [Member]
Line of Credit Facility [Line Items]
Remaining available balance	$ 6,100,000	$ 6,100,000
Term Loan B [Member] | JP Morgan Chase Bank [Member]
Line of Credit Facility [Line Items]
Line of credit facility				8,000,000
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Current borrowings under credit facility	3,780,000	3,780,000
Remaining available balance	$ 6,175,000	$ 6,175,000	$ 9,882,000
Revolving Credit Facility [Member] | JP Morgan Chase Bank [Member]
Line of Credit Facility [Line Items]
Line of credit facility				$ 10,000,000
CBFR Loans [Member]
Line of Credit Facility [Line Items]
Interest on the credit facility, description		CBFR Loan, which bears interest at a per annum rate equal to (a) the Lender’s prime rate or (b) LIBOR for a 30-day interest period, plus 2.50%, in each case, plus a margin ranging from -0.75% to -0.25%.
Credit Facility [Member]
Line of Credit Facility [Line Items]
Minimum fixed charge coverage ratio	125.00%	125.00%
Minimum net worth	$ 37,500,000	$ 37,500,000
LIBOR [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate	2.50%
Effective fixed interest rate	2.93%	2.93%
Debt instrument floor rate	0.43%
LIBOR [Member] | CBFR Loans [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate		2.50%
Eurodollar [Member]
Line of Credit Facility [Line Items]
Interest on the credit facility, description		Eurodollar Loan, which bears interest at a per annum rate equal to LIBOR, plus a margin ranging from 2.00% to 2.50%
Maximum [Member] | Credit Facility [Member]
Line of Credit Facility [Line Items]
Leverage ratio for remainder period		300.00%
Maximum [Member] | LIBOR [Member] | CBFR Loans [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate		(0.75%)
Maximum [Member] | Eurodollar LIBOR Rate [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate		2.50%
Minimum [Member] | Credit Facility [Member]
Line of Credit Facility [Line Items]
Leverage ratio for remainder period		225.00%
Minimum [Member] | LIBOR [Member] | CBFR Loans [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate		(0.25%)
Minimum [Member] | Eurodollar LIBOR Rate [Member]
Line of Credit Facility [Line Items]
Effective floating interest rate		2.00%

Debt - Summary of Revolver Base

Debt - Summary of Revolver Based upon Borrowers' Eligible Accounts Receivable and Inventory (Detail) - Revolving Credit Facility [Member] - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Line of Credit Facility [Line Items]
Gross Availability	$ 10,000	$ 10,000
Outstanding Draws	(3,780)
Letter of Credit		(81)
Landlord Reserves	(45)	(37)
Availability on Revolver	$ 6,175	$ 9,882

Debt - Summary of Future Maturi

Debt - Summary of Future Maturities of Loans and Capital Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Line of Credit Facility [Line Items]
2,016	$ 3,241
2,017	7,298
2,018	6,326
2,019	5,082
2,020	15,663
Total	37,610	$ 34,810
Unamortized value of the debt issuance costs, 2016	(25)
Unamortized value of the debt issuance costs, 2017	(31)
Unamortized value of the debt issuance costs, 2018	(31)
Unamortized value of the debt issuance costs, 2019	(31)
Unamortized value of the debt issuance costs, 2020	(8)
Unamortized value of the debt issuance costs, Total	(126)	(134)
Term Loan A [Member]
Line of Credit Facility [Line Items]
2,017	3,860
2,018	3,860
2,019	3,860
2,020	9,630
Total	21,210
Term Loan B [Member]
Line of Credit Facility [Line Items]
2,016	681
2,017	908
2,018	1,136
2,019	1,136
2,020	2,261
Total	6,122
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
2,020	3,780
Total	3,780
Capital Leases [Member]
Line of Credit Facility [Line Items]
2,016	2,585
2,017	2,561
2,018	1,361
2,019	117
Total	$ 6,624	$ 6,420

Debt - Summary of Future Matu33

Debt - Summary of Future Maturities of Loans and Capital Leases (Parenthetical) (Detail) - Term Loan A [Member] $ in Thousands	Mar. 31, 2016USD ($)
Line of Credit Facility [Line Items]
Prepaid principal payment amount	$ 2,895
June 30, 2016 [Member]
Line of Credit Facility [Line Items]
Prepaid principal payment amount	965
September 30, 2016 [Member]
Line of Credit Facility [Line Items]
Prepaid principal payment amount	965
December 31, 2016 [Member]
Line of Credit Facility [Line Items]
Prepaid principal payment amount	$ 965

Debt - Summary of Company's Cur

Debt - Summary of Company's Current and Long-Term Debt (Including Capital Leases) (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Line of Credit Facility [Line Items]
Current portion of long-term debt	$ 5,177	$ 5,060
Long-Term Debt	32,433	29,750
Total	37,610	34,810
Unamortized value of the debt issuance costs, Current Portion of Long-Term Debt	0	0
Unamortized value of the debt issuance costs, Long-Term Debt	(126)	(134)
Unamortized value of the debt issuance costs, Total	(126)	(134)
Term Loans [Member]
Line of Credit Facility [Line Items]
Current portion of long-term debt	1,873	1,873
Long-Term Debt	25,459	26,651
Total	27,332	28,524
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Long-Term Debt	3,780
Total	3,780
Capital Leases [Member]
Line of Credit Facility [Line Items]
Current portion of long-term debt	3,304	3,187
Long-Term Debt	3,320	3,233
Total	$ 6,624	$ 6,420

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 384	$ (285)
Effective income tax rate	40.90%	40.80%

Earnings (Loss) Per Share - Num

Earnings (Loss) Per Share - Numerators and Denominators of Basic and Diluted Income (Loss) per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Numerator:
Net income (loss)	$ 495	$ (415)
Weighted average common shares outstanding:
Basic	22,548,538	22,308,730
Dilutive effect of non-vested awards	490,718
Diluted	23,039,256	22,308,730
Net income (loss) per share:
Basic	$ 0.02	$ (0.02)
Diluted	$ 0.02	$ (0.02)

Earnings (Loss) Per Share - Add

Earnings (Loss) Per Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Stock Options [Member]
Summary Of Significant Accounting Policies [Line Items]
Shares with anti-dilutive effect	0.1	0.3

Recent Accounting Pronounceme38

Recent Accounting Pronouncements and Developments - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)
Accounting Changes and Error Corrections [Abstract]
Reduction in other assets	$ 0.1
Reduction in long-term debt	$ 0.1